Exelixis, Inc. (EXEL)

NASDAQ: EXEL · Delayed Price · USD
19.49
-1.20 (-5.80%)
At close: May 18, 2022 4:00 PM
19.46
-0.03 (-0.15%)
Pre-market:May 19, 2022 7:22 AM EDT
Market Cap6.25B
Revenue (ttm)1.52B
Net Income (ttm)298.04M
Shares Out320.74M
EPS (ttm)0.72
PE Ratio27.07
Forward PE20.00
Dividendn/a
Ex-Dividend Daten/a
Volume4,493,826
Open20.46
Previous Close20.69
Day's Range19.45 - 20.73
52-Week Range15.50 - 24.75
Beta0.78
AnalystsBuy
Price Target27.71 (+42.2%)
Earnings DateMay 10, 2022

About EXEL

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, inclu...

IndustryBiotechnology
IPO DateApr 7, 2000
Employees954
Stock ExchangeNASDAQ
Ticker SymbolEXEL
Full Company Profile

Financial Performance

In 2021, Exelixis's revenue was $1.43 billion, an increase of 45.31% compared to the previous year's $987.54 million. Earnings were $231.06 million, an increase of 106.71%.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is 27.71, which is an increase of 42.18% from the latest price.

Price Target
$27.71
(42.18% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Can This Cancer Stock Maintain Its Momentum?

This biotech stock has been on fire since the beginning of the year.

22 hours ago - The Motley Fool

Buying These 3 Stocks Could Be the Smartest Investing Move You Ever Make

With thrilling long-term prospects, these three are excellent buys.

Other symbols:ETSYISRG
1 day ago - The Motley Fool

Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates

Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.

1 week ago - Zacks Investment Research

Exelixis (EXEL) Tops Q1 Earnings Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate objective...

1 week ago - Business Wire

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

Other symbols:BHCCPRXEPZMRETA
1 week ago - Zacks Investment Research

Why Exelixis (EXEL) Might Surprise This Earnings Season

Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 week ago - Zacks Investment Research

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences in ...

2 weeks ago - Business Wire

3 Growth Stocks to Buy With $1,000 Right Now

A small investment can go a long way.

Other symbols:CURLFPINS
2 weeks ago - The Motley Fool

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previou...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a monotherapy ...

2 weeks ago - Business Wire

Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022 after the markets close. At 5:00 p...

3 weeks ago - Business Wire

Stock Market Bounces, But Be Wary; Watch Exelixis, World Wrestling Entertainment, Marriott

Stock Market Bounces, But Be Wary; Watch Exelixis, World Wrestling Entertainment, Marriott Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, in...

Other symbols:MARWWE
3 weeks ago - Investors Business Daily

7 Top-Rated Biotech Stocks to Buy for Q2

In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.

4 weeks ago - InvestorPlace

Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?

Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.

4 weeks ago - Zacks Investment Research

Exelixis (EXEL) Initiates Early Stage Study of Lymphoma

Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.

1 month ago - Zacks Investment Research

Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgk...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of the first-in-human phase 1 trial of XL114, a novel anti-cancer compound that in...

1 month ago - Business Wire

Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Charles Cohen, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors. Dr. Coh...

1 month ago - Business Wire

Nasdaq Bear Market: 3 of the Safest Stocks to Buy on the Dip

A tumbling market is the perfect time to invest in these pillars of stability.

Other symbols:AVGO
1 month ago - The Motley Fool

Here's Why Exelixis (EXEL) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

1 month ago - Zacks Investment Research

3 No-Brainer Stocks to Buy With $1,000 During the Market Sell-Off

A tumbling market is the perfect opportunity to buy into these highly profitable and attractively priced stocks.

Other symbols:AVGOFB
1 month ago - The Motley Fool

2 Stocks Defying the Market Sell-Off Right Now

Are these two companies solid long-term bets?

Other symbols:BMY
1 month ago - The Motley Fool

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Tre...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the sci...

1 month ago - Business Wire

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 month ago - Zacks Investment Research

Exelixis (EXEL) Announces Final Results From HCC Study

Exelixis (EXEL) does not intend to submit a supplemental new drug application to the FDA for Cabometyx in patients with previously untreated advanced hepatocellular carcinoma.

2 months ago - Zacks Investment Research

Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with a...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial,...

2 months ago - Business Wire